Esaxerenone significantly reduced morning home BP as well as bedtime home and office BP, and also significantly decreased UACR and NT-proBNP in patients with essential hypertension inadequately controlled with an ARB or a CCB. The gene discussed is NPPB; the disease is hypertensive disorder.